H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Strata Skin Sciences Inc (SSKN) today and set a price target of $5. The company’s shares closed yesterday at $2.12.
Pantginis wrote:
“Valuation and risks to price target achievement. We maintain our Buy rating with a price target of $5. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, XTRAC, and project upside from: (1) increase in patients treated for lead indication psoriasis; and (2) increasing traction for XTRAC in its other approved indications, vitiligo and eczema/atopic dermatitis. This model allows us to flex multiple assumptions affecting a drug or device’s potential commercial profile.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -4.3% and a 34.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.
Strata Skin Sciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $6, representing a 183.0% upside. In a report issued on May 14, Northland Securities also assigned a Buy rating to the stock with a $7 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.88 and a one-year low of $1.56. Currently, Strata Skin Sciences Inc has an average volume of 63.66K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STRATA Skin Sciences, Inc. is a medical technology company, which engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
